Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …

Recent research into the pathophysiology and treatment of atopic dermatitis (AD) has shown
notable progress. An increasing number of aspects of the immune system are being …

Background Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13,
prevents the formation of the interleukin-4Rα–interleukin-13Rα1 heterodimer receptor …

Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with heterogenous
presentation and often immense patient burden. Safe, targeted treatment options are …

Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly
overlap in the human interactome. The concept of “one‐airway‐one‐disease,” coined over …

Dupilumab, an IL4R-blocking antibody, has shown clinical efficacy for atopic dermatitis (AD)
treatment. In addition to conjunctivitis/blepharitis, the de novo appearance of head/neck …

The discovery in 2006 that loss-of-function mutations in the filaggrin gene (FLG) cause
ichthyosis vulgaris and can predispose to atopic dermatitis (AD) galvanized the dermatology …

Atopic dermatitis (AD) is a common, chronic-relapsing inflammatory skin disease with
significant disease burden. Genetic and environmental trigger factors contribute to AD …

Atopic dermatitis (AD) is the most common inflammatory skin disease, and it is considered a
complex and heterogeneous condition. Different phenotypes of AD, defined according to the …

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases, which
generally presents with intense itching and recurrent eczematous lesions. AD affects up to …